In this interview, we speak to to Keith Kaye, Principle Investigator of the RESTORE-1 trial assessing relebactam in combination with imipenem (IMI/REL), about the trial’s results and the implications these have for clinicians in ‘real world’ settings.
Browsing: Clinical Trial
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
A Phase III study, TANGO II, has reported that meropenem–vaborbactam monotherapy for CRE infections was associated with improvement in clinical cure rates, lower nephrotoxicity and lower mortality versus best-available therapy.
Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Continuous mass distribution of azithromycin in northern Ethiopia is effective for trachoma prevention but doesn’t eliminate the disease entirely, according to new research.
ViiV Healthcare has announced positive 48-week results from its Phase III ATLAS study of a long-acting, injectable, two-drug regimen for treating HIV.
A study in 20 patients has demonstrated that transplantation followed by antiviral therapy has been successful in patients receiving kidneys from hepatitis C-infected donors.
Glenn Tillotson gives us an overview of the 14th Biennial Congress of the Anaerobe Society of the Americas, including updates on the microbiome and new therapies.
ViiV healthcare has announced results of a 100-week Phase lll program and demonstrated the success of the first two-drug regimen, Juluca®.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.